Try
Arcutis Biotherapeutics, Inc.
ARQTUnited States
35 filed reports · 349 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
35 reports · Mar 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 10 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 20 | 3,180 | Mar 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,688 | Dec 2020 to Dec 2025 |
| Current · 8-KSEC EDGAR | 4 | 10 | Dec 2024 to Jun 2026 |
| Quarterly · 10-Q/ASEC EDGAR | 3 | 3 | Mar 2023 to Mar 2024 |
| Annual · 10-K/ASEC EDGAR | 2 | 2 | Dec 2021 to Dec 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 363 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 5, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 213 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 811 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 28, 2025 | 239 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 28, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 136 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 156 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 444 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Jan 13, 2025 | 4 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 148 | Open |
Financial data
349 concepts · 5,883 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial333 concepts · 5,588 facts · Dec 2018 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents39 · Dec 2018 to Jun 2026
- Stockholders equity (US GAAP)39 · Dec 2018 to Jun 2026
- Accretion amortization of discounts and premiums investments38 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Dec 2018 to Jun 2026
- Allocated share based compensation expense38 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect38 · Dec 2018 to Jun 2026
- Comprehensive income net of tax38 · Dec 2018 to Jun 2026
- Increase decrease in accounts payable38 · Dec 2018 to Jun 2026
- Increase decrease in accrued liabilities38 · Dec 2018 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets38 · Dec 2018 to Jun 2026
- Net cash provided by used in financing activities38 · Dec 2018 to Jun 2026
- Net cash provided by used in investing activities38 · Dec 2018 to Jun 2026
- Net cash provided by used in operating activities38 · Dec 2018 to Jun 2026
- Net income loss38 · Dec 2018 to Jun 2026
- Operating income loss38 · Dec 2018 to Jun 2026
- Operating lease liabilities38 · Dec 2018 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax38 · Dec 2018 to Jun 2026
- Payments to acquire available for sale securities debt38 · Dec 2018 to Jun 2026
- Payments to acquire property plant and equipment38 · Dec 2018 to Jun 2026
- Proceeds from stock options exercised38 · Dec 2018 to Jun 2026
- Research and development expense38 · Dec 2018 to Jun 2026
- Share based compensation38 · Dec 2018 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding intrinsic value36 · Dec 2018 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding number36 · Dec 2018 to Jun 2026
Segment14 concepts · 207 facts · Dec 2022 to Jun 2026
- Research and development expense46 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- Costs and expenses14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Interest expense nonoperating14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Operating income loss14 · Dec 2022 to Jun 2026
- Other nonoperating income expense14 · Dec 2022 to Jun 2026
- Reportable Segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Interest income other5 · Dec 2023 to Mar 2026
- Investment income interest2 · Jun 2025 to Jun 2026
Product1 concepts · 78 facts · Dec 2020 to Jun 2026
- Revenue78 · Dec 2020 to Jun 2026
Guidance1 concepts · 10 facts · Jan 2025 to Aug 2026
- Revenue Guidance10 · Jan 2025 to Aug 2026
Segments
285 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 207 facts
- Reportable207 · Dec 2022 to Jun 2026
Product or service7 members · 78 facts
- ZORYVE Foam18 · Dec 2022 to Jun 2026
- ZORYVE Cream0.1516 · Dec 2022 to Jun 2026
- ZORYVE Cream0.315 · Dec 2022 to Jun 2026
- Product10 · Dec 2020 to Dec 2023
- Other Revenue7 · Dec 2021 to Dec 2023
- ZORYVE Cream0.057 · Dec 2023 to Jun 2026
- ZORYVE Cream5 · Mar 2023 to Mar 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.